|
|
|
| home > white papers > Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts - Eurofins BioPharma Product Testing |
|
|
 WHITE PAPERS |
|
Eurofins BioPharma Product Testing
|
|
Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts
|
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Signant Health Enhances Audit Trail Reporting Capabilities in TrialMax® to Improve eCOA Data Integrity Monitoring
PHILADELPHIA, PA – 29th January, 2020: Signant Health has announced new audit trail reviewing and reporting functionality today for its electronic clinical outcome assessment (eCOA) and remote sensor platform, TrialMax®.
More info >> |
|
 |
White Papers |
 |
|
High Potency Drugs – from Molecule to Market
PCI Pharma Services
PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >> |
|
 |
Industry Events |
 |
INTERPHEX 2020
28-30 April 2020, Javits Center NYC
More info >> |
|
|
|
